Edgewise Therapeutics, Inc. (EWTX) Cash Flow Statement
Edgewise Therapeutics, Inc. (EWTX) generated -$158.4M of operating cash flow over the twelve months to 2026-06-30, spent $454000 on capital expenditure and had free cash flow of -$158.8M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
EWTXEdgewise Therapeutics, Inc.Follow EWTX — free
—
Price chart with a free account
- Market cap
- 4.3B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 11 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -33.5 | -52.6 | -91.9 | -109.0 | -143.8 | -158.4 | |
| Capital expenditure | 0.7 | 5.5 | 5.7 | 1.3 | 0.3 | -0.5 | |
| Free cash flow | -34.2 | -58.2 | -97.7 | -110.3 | -144.1 | -158.8 | |
| Stock-based compensation | 4.4 | 10.9 | 17.6 | 24.7 | 34.8 | — |
USD millions · SEC XBRL
Edgewise Therapeutics, Inc. — questions
- What is Edgewise Therapeutics, Inc.'s operating cash flow?
- -$158.4M over the twelve months to 2026-06-30.
- How much does Edgewise Therapeutics, Inc. spend on capital expenditure?
- $454000 over the twelve months to 2026-06-30.
- What is Edgewise Therapeutics, Inc.'s free cash flow?
- -$158.8M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Edgewise Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.